Interleukin-6 as a prognostic biomarker in repatocellular carcinoma treated with systemic therapy: a systematic review and meta-analysis.
BACKGROUND AND AIMS Interleukin-6 (IL-6) has been implicated in the pathogenesis of hepatocellular carcinoma (HCC) and resistance to systemic therapy. This study aimed to evaluate the prognostic value of circulating IL-6 in patients with HCC receiving systemic therapy through a systematic review and meta-analysis. ME...